Likewise, a different pool of T-cells, including CD41 T-helper Type 1 and 2 cells, CD41 regulatory T-cells and CD81 T-cells, reactive to several HPV-16 E6 and E7 epitopes were observed and the local presence of HPV-16-specific T-cell immunity acts in the antitumor response and support the development of immunotherapy for HNSCC (37, 38). This evidence concerns the gene CD81 and head and neck squamous cell carcinoma.